The New York Times, May 6, 2020

Link

All viruses mutate, and the coronavirus is no exception. But there is no compelling evidence yet that it is evolving in a way that has made it more contagious or more deadly.

A preprint study — posted online, but not published in a scientific journal and not yet peer-reviewed — has set the internet afire by suggesting otherwise.

On April 30, a report by a team led by Bette Korber, a biologist at Los Alamos National Laboratory in New Mexico, claimed to have found a mutation in the coronavirus that arose in Europe in February and then rapidly spread, becoming dominant as the virus was introduced into new countries.

Continue reading “Did a Mutation Turbocharge the Coronavirus? Not Likely, Scientists Say”

The New York Times, May 5, 2020

Link

A team of scientists has developed an experimental prototype for a fairly quick, cheap test to diagnose the coronavirus that gives results as simply as a pregnancy test does.

The test is based on a gene-editing technology known as Crispr, and the researchers estimated that the materials for each test would cost about $6.

“We’re excited that this could be a solution that people won’t have to rely on a sophisticated and expensive laboratory to run,” said Feng Zhang, a researcher at the Broad Institute in Cambridge, Mass., and one of the pioneers of Crispr technology.

Continue reading “With Crispr, a Possible Quick Test for the Coronavirus”

The New York Times, May 2, 2020 (David E. Sanger, David D. Kirkpatrick, Katie Thomas and Sui-Lee Wee)

Link

WASHINGTON — Four months after a mysterious new virus began its deadly march around the globe, the search for a vaccine has taken on an intensity never before seen in medical research, with huge implications for public health, the world economy and politics.

Seven of the roughly 90 projects being pursued by governments, pharmaceutical makers, biotech innovators and academic laboratories have reached the stage of clinical trials. With political leaders — not least President Trump — increasingly pressing for progress, and with big potential profits at stake for the industry, drug makers and researchers have signaled that they are moving ahead at unheard-of speeds.

Continue reading “Profits and Pride at Stake, the Race for a Vaccine Intensifies”

It’s been another hard month. When I last sent out a newsletter on March 29, the United States had suffered 2,201 deaths from Covid-19. Today the total has reached 64,203.

That is the official count, but the full count is far higher. In cities like New York, the total number of deaths has jumped well above the average rate for this time of year. There aren’t enough tests to go around, so we’re not getting a full count of the sick. Many people are dying at home. Continue reading “Friday’s Elk, May 1, 2020”

The New York Times, May 1, 2020

Link

The world is eager to come out of lockdown. But if countries simply return to business as usual, new outbreaks of Covid-19 will follow. The only solution that public health experts see is to keep careful track of the coronavirus and clamp down on new flare-ups.

The trouble is that the most obvious way to monitor the virus — testing person by person — has already proved to be a huge, expensive challenge. Experts say we’re nowhere near the scale we need to get a good picture of the pandemic.

Continue reading “Is It Safe to Come Out of Lockdown? Check the Sewer”